References
1. Savel’eva G.M., Kurtser M.A., Panina O.B., Sichinava L.G., Klimenko P.A., Konoplyannikov A.G., Alekseenkova M.V. Diagnosis, treatment, prevention of fetal hemolytic disease in RH-sensitization. Rossiyskiy vestnik perinatologii i pediatrii. 2006; 6: 73–8. (in Russian)
2. Scott M.L. The complexities of the Rh system. Vox Sang. 2004; 87: 58–62.
3. Rh-sensitization. Hemolytic disease of the fetus. Clinical recommendations. Letter dated 18 May 2017 No. 15-4/10/2-3300 Ministry of Health of the Russian Federation. Moscow, 2017. (in Russian)
4. Guideline on the clinical investigation of human anti-D immunoglobulin for intravenous and/or intramuscular use: EMA/CPMP/BPWG/575/99, rev. 1 URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003334.pdf.
5. MacKenzie I.Z., Roseman F., Thompson K. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. BJOG. 2006; 113: 96–8.
6. Hannafin B., Lovecchio F., Blackburn P. Do Rh-nagative women with first trimester spontaneous abortions need Rh immune globulin? Emerg. Med. J. 2006; 24: 487–90.
7. Connan K. IVIG – is it the answer? Maternal administration of immunoglobulin for severe red cell alloimmunization during pregnancy: a case series. Obstet. Anesth. Digest. 2011; 31 (1): 43–5.
8. Polyak R., Katu R., Karush F. Immunoglobulins. Moscow: Mir, 1981: 495 p. (in Russian)
9. Frimel’ Kh. Immunological methods. Moscow: Mir, 1979: 518 p. (in Russian)
10. Givol D., Reisfeld R.A., Mandy W.J. Structural analysis of antibody combining site. In: Contemporary Topics in Molecular Immunology. Vol. 2. New York: Plenum Press, 1973: 27–50.
11. Khaitov R.M. Immunology: a textbook. 2nd ed. Moscow: Meditsina, 2002: 536 p. (in Russian)
12. Donskov S.I. Blood groups of the Rhesus system. Theory and practice. Moscow: VINIT i RAN, 2005: 392 p. (in Russian)
13. WHO: 28th report. Expert Committee on Biological Standardization. WHO Tech. Rep. Ser. 1977; 610: 29–31.
14. Paul E.B. Standardization of US reference Rho(D) immune globulin by quantitative automated hemagglutination. J. Biol. Stand. 1986; 14: 121–25.
15. Trope S.J., Sands D., Fox B., Behr-Gross M.-E. A global standard for anti-D immunoglobulin: international collaborative study to evaluate a candidate preparation. Vox Sang. 2003; 85 (4): 313–21.
16. Herbert W.J. Passive hemagglutination. In: D.M. Weir (ed.). Handbook of Experimental Immunology. Oxford; Edinburgh: Blackwell Scientific Publications, 1967.
17. Assay of Human Anti-D Immunoglobulin: European Pharmacopoeia. 9th ed. Strasboung: Directorate for the Quality of Medicines of the Council of Europe.
18. Donskov S.I. D antigen expression. In: Human Blood Groups: a Guide to Immunoserology. Moscow: IP Skorokhodov V.A., 2011: 1016 p. (in Russian)
19. Zhiburt E.B. Immunological bases of blood transfusion. In: Transfusion: a textbook. Saint Petersburg: Piter, 2002: 736 p. (in Russian)
20. Trope S.J., Sands D., Rautmann. International collaborative study to evaluate methods for quantification of anti-D in immunoglobulin preparations. Vox Sang. 2002; 83: 42–9.
21. Trope S.J., Fox B., Turner C. Competitive enzyme-linked immunoassay of monoclonal immunoglobulin G anti-D preparations. Transfus. Med. 2003; 13 (3): 209–12.
22. Dmitriev D.A., Massino Yu.S., Segal O.L. Kinetic analysis of interactions between bispecific monoclonal antibodies and immobilized antigens using a resonant mirror biosensor. J. Immunol. Methods. 2003; 280: 183–99.
23. Trope S.J., Fox B., Sands D. A stable lyophilized reagent for use in a potential reference assay for quantitation of anti-D in immunoglobulin products. Biologicals. 2002; 30: 315–21.
24. Schaffner G., Kayser T., Tonjes A. Validation of flow cytometry to quantify the potency of anti-D immunoglobulin preparations. Vox Sang. 2003; 84: 129–36.
25. Austin E.B., McIntosh Y., Hodson C. Anti-D quantitation by flow cytometry: an alternative to the Autoanalyzer? Transfus. Med. 1995; 5: 203–10.
26. Dubinkin I.V., Donskov S.I., Piskunova T.M. Serological characteristics of monoclonal antibodies to Rh-Hr and Kell antigens. In: Materials of Transfusiology and Clinical Medicine Conference. Kirov, 2005: 156–7. (in Russian)
27. Trusov G.A., Chaplenko A.A., Semenova I.S. Use of flow cytometry to quality evaluation of biomedical cell products. Biopreparaty. 2018; 18 (1): 16–4. (in Russian)
28. International collaborative study to calibrate proposed 3rd WHO International Standard for anti-D Immunoglobulin. WHO Expert Committee on Biological Standardization. WHO/BS/2018.2332 URL: https://www.who.int/biologicals/BS.2018.2332_3rd_IS_ANTI-D.pdf.
29. Manylova N.A., Loginova I.I. Using the Kleihauer-Betke test in revealing of fetomaternal transfusion and determination of risk factors of anemia in newborns of the first week of life. Systemniy analys i upravlenie v biomeditsinskikh systemakh. 2008; 7 (1): 142–4. (in Russian)
30. Manylova N.A., Logvinova I.I., Krutskikh E.L., Karamova L.N., Gudkova A.N. The study of the blood of childbirth on fetal red blood cells for the diagnosis fetomaternal transfusion. In: Materials of the 2nd Scientific and Practical Conference Dedicated to the 120th Anniversary of Voronezh Hospital No. 10. Voronezh, 2008: 42–7. (in Russian)
31. Kurtser M.A. Prevention of hemolytic disease. Vestnik RGMU. 2008; 6: 43–7. (in Russian)
32. American College of Obstetricians and Gynecologists. Management of alloimmunization. ACOG Pract. Bull. 2006; 5.
33. Human immunoglobulin: GPA.1.8.1.003.15. State Pharmacopoeia of the Russian Federation. XIV ed. URL: http://resource.rucml.ru/feml/pharmacopia/14_2/HTML/1271/index.html. (in Russian)
34. Bioanalytical method validation guidance for industry. U.S. Biopharmaceutics, May 2018. URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
35. ICH guidelines for the pharmaceutical industry. Quality. In: Beregovykh V.V. (ed.). Saint Petersburg: Professiya, 2017: 768 p. (in Russian)